Literature DB >> 9268170

Recognition of dengue virus NS1-NS2a proteins by human CD4+ cytotoxic T lymphocyte clones.

S Green1, I Kurane, S Pincus, E Paoletti, F A Ennis.   

Abstract

We examined nine dengue virus-specific human CD4+ CD8- cytotoxic T lymphocyte (CTL) clones for protein recognition, using recombinant vaccinia viruses which contain genes coding for dengue virus proteins. These clones were established from peripheral blood mononuclear cells of a donor previously immunized with a live-attenuated experimental dengue-1 vaccine. Of nine CD4+ T cell clones, seven were dengue-1-specific and two were dengue-1-dengue-3 cross-reactive. Four dengue-1-specific clones and one dengue-1-dengue-3 cross-reactive clone recognized epitopes within the NS1 or NS2a proteins. Analysis of human leukocyte antigen (HLA) restriction revealed that three dengue-1-specific clones are HLA-DR1-restricted and one dengue-1-dengue-3 cross-reactive clone is HLA-DPw3-restricted. These results indicate that NS1 and NS2a proteins as well as C, E, and NS3 proteins reported earlier contain one or more epitopes recognized by dengue virus-specific human CD4+ T lymphocytes.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9268170     DOI： 10.1006/viro.1997.8648

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  13 in total

Review 1.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

Review 2.  Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections.

Authors:  Anuja Mathew; Elizabeth Townsley; Francis A Ennis
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

3.  The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes.

Authors:  E Konishi; M Yamaoka; I Kurane; K Takada; P W Mason
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

4.  CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system.

Authors:  Elizabeth M Sitati; Michael S Diamond
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

5.  A human CD4+ T cell epitope in the influenza hemagglutinin is cross-reactive to influenza A virus subtypes and to influenza B virus.

Authors:  Jenny Aurielle B Babon; John Cruz; Francis A Ennis; Liusong Yin; Masanori Terajima
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

6.  Strong ability of Nef-specific CD4+ cytotoxic T cells to suppress human immunodeficiency virus type 1 (HIV-1) replication in HIV-1-infected CD4+ T cells and macrophages.

Authors:  Nan Zheng; Mamoru Fujiwara; Takamasa Ueno; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

Review 7.  Evasion of the human innate immune system by dengue virus.

Authors:  Sarah Pagni; Ana Fernandez-Sesma
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

8.  T-cell responses to dengue virus in humans.

Authors:  Ichiro Kurane; Takaji Matsutani; Ryuji Suzuki; Tomohiko Takasaki; Siripen Kalayanarooj; Sharone Green; Alan L Rothman; Francis A Ennis
Journal:  Trop Med Health       Date:  2011-12-01

9.  Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL.

Authors:  Nagendra R Hegde; Claire Dunn; David M Lewinsohn; Michael A Jarvis; Jay A Nelson; David C Johnson
Journal:  J Exp Med       Date:  2005-10-10       Impact factor: 14.307

10.  Identification of conserved and HLA promiscuous DENV3 T-cell epitopes.

Authors:  Eduardo J M Nascimento; Robbie B Mailliard; Asif M Khan; John Sidney; Alessandro Sette; Nicole Guzman; Michael Paulaitis; Andréa Barbosa de Melo; Marli T Cordeiro; Laura V G Gil; Françoir Lemonnier; Charles Rinaldo; J Thomas August; Ernesto T A Marques
Journal:  PLoS Negl Trop Dis       Date:  2013-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.